The End of an Era: FDA Announces Disposition Plans for COVID-19 Related Guidance Documents | Wiley Rein LLP

The COVID-19 pandemic presented the U.S. Food and Drug Administration (FDA or Agency) with a monumental task of shifting its operations and the way it approached the regulation of...

Related Keywords

,Health Care Professionals ,Public Health Emergency On Formal Meetings ,Drug Administration ,Development Of Abbreviated New Drug Applications During ,Public Health Emergency ,Public Health Emergency Revised ,Health Emergency ,Federal Register ,Guidance Documents That Will Expire With ,Transition Plan ,Investigational Cellular ,Gene Therapy Products During ,Abbreviated New Drug Applications During ,Formal Meetings ,User Fee Applications Questions ,Certain Drugs ,Hospitalized Patients ,Outsourcing Facilities During ,General Considerations ,Biological Products ,Quite Finished ,Guidance Documents That Will Remain ,Supply Chain ,Biological Product Inspections During ,Health Emergency Questions ,Face Shields ,Surgical Masks ,Respirators During ,Gloves During ,Molecular Influenza ,Emergency Use Authorizations ,Use Authorization ,Clinical Trials ,Medical Products During ,Review Board ,Individual Patient Expanded Access Requests ,Investigational New Drugs ,Biological Products During ,Health Emergency Guidance ,Clinical Investigators ,Interactive Evaluations ,Drug Manufacturing ,Bioresearch Monitoring Facilities During ,Approved Premarket Approval ,Humanitarian Device Exemption Submissions During ,Long Haul ,Guidance Documents Not Impacted ,Specific Guidance ,Adverse Event Reporting ,Medical Products ,Dietary Supplements During ,Evaluating Impact ,Viral Mutations ,